Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 3,870 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sexually Transmitted Diseases, Viral Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects

NCT01101893
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Raltegravir, GSK2248761, GSK2248761 + Raltegravir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 3 Interventional

A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.

NCT00002093
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Daunorubicin (liposomal), Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride
Drug
Lead sponsor
Nexstar Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palm Springs, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected People

NCT00100633
View directory record Official record
Conditions
HIV Infections, Hepatitis B
Interventions
CpG7909 oligodeoxynucleotides (ODN), Hepatitis B virus vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2008 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Not applicable Interventional

A Study of Lobucavir in Patients With AIDS

NCT00002352
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Lobucavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Francisco, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of the EnvPro HIV Vaccine in Healthy Volunteers

NCT00076947
View directory record Official record
Conditions
HIV Infections
Interventions
EnvPro
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 21, 2008 · Synced Oct 14, 2026, 10:59 PM EDT
Recruiting Phase 2 Interventional

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption

NCT05419024
View directory record Official record
Conditions
HIV
Interventions
Acute Treatment Interruption
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Not applicable Interventional Results available

iTransition Development

NCT04383223
View directory record Official record
Conditions
Human Immunodeficiency Virus, HIV Seropositivity
Interventions
iTransition
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 3 Interventional

Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

NCT00001013
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimetrexate glucuronate, Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
23
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 1 Interventional

Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects

NCT00623259
View directory record Official record
Conditions
HIV Infections
Interventions
MVA-mBN120B
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 20, 2010 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Not applicable Interventional Results available

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

NCT00814879
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections
Interventions
Raltegravir, Atazanavir, Standard treatment regimen
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
New Haven, Connecticut • Waterbury, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 14, 2026, 10:59 PM EDT
Terminated No phase listed Observational

Viral and Host Factors in the Transmission and Pathogenesis of HIV

NCT00219947
View directory record Official record
Conditions
HIV Infections
Interventions
blood draw
Other
Lead sponsor
Rockefeller University
Other
Eligibility
16 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 14, 2026, 10:59 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity

NCT02499978
View directory record Official record
Conditions
HIV/AIDS
Interventions
Darunavir/Cobicistat, Dolutegravir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Not applicable Interventional

A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients

NCT00002000
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Valacyclovir hydrochloride, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
22
States / cities
Mobile, Alabama • San Francisco, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 10:59 PM EDT
Terminated Phase 1 Interventional

Safety and Tolerability of Z-100 in Patients With Early HIV Infection

NCT00016692
View directory record Official record
Conditions
HIV Infections
Interventions
Z-100
Drug
Lead sponsor
Zeria Pharmaceutical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2006 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Not applicable Interventional

A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection

NCT00000852
View directory record Official record
Conditions
HIV Infections
Interventions
Allogeneic lymphocyte transfer
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Not applicable Interventional

A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS

NCT00002278
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Diclazuril
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
12 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Results available

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

NCT00225017
View directory record Official record
Conditions
HIV Infection, Hyperlipidemia
Interventions
Atazanavir, current antiretroviral regimen
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 1Phase 2 Interventional

Stonewall Treatment Evaluation Project

NCT01129401
View directory record Official record
Conditions
Substance Abuse, HIV Infections
Interventions
Stonewall Project
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 2 Interventional

A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs

NCT00002162
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Development and Evaluation of an HIV, STD, and Pregnancy Prevention Program for Middle School Students

NCT00161382
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases, Pregnancy
Interventions
HIV, STD, and pregnancy prevention curriculum, Standard sexual education curriculum
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
11 Years to 16 Years
Enrollment
3,007 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Oct 14, 2026, 10:59 PM EDT
Recruiting Not applicable Interventional

The Role of the Gastrointestinal-associated Lymphoid Tissue in the Cure of HIV Infection

NCT05652088
View directory record Official record
Conditions
HIV Infection
Interventions
Colonoscopy
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

All About Youth: Evaluation of Sexual Risk Avoidance and Risk Reduction Programs for Middle School Students

NCT00167505
View directory record Official record
Conditions
Sexually Transmitted Diseases, Pregnancy, HIV Infections
Interventions
Risk Avoidance Intervention, Risk Reduction Intervention
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
11 Years to 16 Years
Enrollment
1,742 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2010 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 2 Interventional

Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

NCT00380159
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)-1 Infection
Interventions
Elvucitabine, Lamivudine, Emtricitabine
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Atlanta, Georgia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Not applicable Interventional

A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy

NCT00000969
View directory record Official record
Conditions
HIV Infections
Interventions
Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 14, 2026, 10:59 PM EDT